Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.55 | 7.52393980848 | 7.31 | 8.2591 | 7.21 | 423524 | 7.85918821 | CS |
| 4 | 0.36 | 4.8 | 7.5 | 8.2591 | 7.21 | 366447 | 7.76228705 | CS |
| 12 | -0.54 | -6.42857142857 | 8.4 | 8.95 | 7.21 | 431422 | 8.07932597 | CS |
| 26 | 0.61 | 8.41379310345 | 7.25 | 9.76 | 6.61 | 649008 | 8.16814659 | CS |
| 52 | 1.82 | 30.1324503311 | 6.04 | 9.76 | 4.2 | 567348 | 7.3958204 | CS |
| 156 | 2.21 | 39.1150442478 | 5.65 | 9.76 | 3.89 | 397158 | 6.77477029 | CS |
| 260 | 2.21 | 39.1150442478 | 5.65 | 9.76 | 3.89 | 397158 | 6.77477029 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
